PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q3, 2014/15)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3		Closed - In Follow Up	Y	Study delivered to target. Study has been in follow up since 2008.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CM	5	15/06/2008	Closed - In Follow Up	Y	Study delivered to time and target.
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.			Open	N/A	No target or date agreed with sponsor.
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200		Open	N/A	No date agreed with sponsor. There are 7 recruited to date.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6		Open	N/A	No date agreed with sponsor.
10/H0605/58	Sub Study to study WN25203,using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus AvonexÂ® (Interferon ÃŸ-1a) in patients wih Relapsing-remitting multiple S	6	01/11/2011	Closed - Follow Up Complete	Y	Study delivered to time and target. 7 patients recruited in total.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0717/68	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic	3	25/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasiblity Study	15	17/07/2016	Open	N/A	No target or date agreed with sponsor.
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered oraly once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H1306/5	A phase III open multicentre study to investigate the safety and efficacy of BPL's high purity factor X in the treatement of factor X deficient subjects undergoing surgery.	1	31/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/AL/0322	Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer	2	30/10/2012	Closed - In Follow Up	Y	Study delivered to time and target.

11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2014	Open	N	There are 3 patients recruited into the study. Team continues to try to identify new patients.
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	30/09/2014	Open	Y	Study already delivered to time and target. There are 29 patients recruited to date.
11/LO/0190	A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	8	15/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study delivered to time and target. 33 patients recruited in total.
11/LO/0551	A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid tumors	10	31/01/2015	Open	N/A	No target or date agreed with sponsor.
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C	2		Open	Y	Study delivered to target.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	1	31/08/2014	Open	N	Rare disease study.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus comp	5	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	6	31/05/2013	Open	Y	Study delivered to time and target. Still open.
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/NW/0298	A multicenter, phase Ill, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA1O1 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainten	2	20/12/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Open	Y	Study delivered to time and target.
11/SC/0499	A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PET-MF).	1	31/08/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	1	31/03/2015	Open	Y	Study delivered to time and target. Still open.
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/01/2013	Open	N	Study reached target in February 2014.
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inad	5	01/01/2014	Open	N	2 patients recruited to date.

12/EE/0231	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of Nâ€“Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone			Withdrawn	N/A	No target or date agreed with sponsor.
12/EE/0400	GS-US-334-0109 Â– An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	1		Closed - In Follow Up	Y	Study delivered to target. 4 patients recruited in total.
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment NaÃ¯ve Subjects with Chronic He	5		Closed - In Follow Up	Y	Study delivered to target.
12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids	6	01/08/2013	Open	Y	Study delivered to time and target. Still open.
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor Villa Variant (813), in adult Hemophilla A and B Subjects with or without inhibitors	1	30/04/2014	Open	N	Rare disease study. Study suspended by Sponsor before first patient consented at all sites. Strict/difficult dosing schedule. Major protocol amendments approved May 2013.
12/LO/0858	An OpenLabel Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon Î±2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects			Open	N/A	No target or date agreed with sponsor.
12/LO/0923	A Phase 3, randomized, doubleblind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castrationresistant prostate cancer	3	30/06/2015	Withdrawn	N/A	No target or date agreed with sponsor. Sponsor paused screening 2 weeks after R&D approval at site, and subsequently closed recruitment prematurely at all sites.
12/LO/0980	PROTOCOL EC-FV-06: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING VINTAFOLIDE (EC145) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXILÂ®/CAELYXÂ®) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER	5	31/01/2015	Withdrawn	N/A	Data Safety Monitoring Board recommended early closure of the study and Sponsor agreed.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	10	31/08/2014	Open	Y	Study delivered to time and target.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	Target reached but 2 months later than agreed date.
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	Y	Study delivered to time and target. Target reached 12 months ahead of date agreed.
12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment Â–experienced adults with genotype 1 chronic hepat	5	01/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (T	4	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short	10	31/12/2014	Open	N	Recruitment has been difficult globally. Several other sites have also not reached their target. Study team has spoken to many possible participants but they have declined to take part.
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-NaÃ¯ve Subjects with Chroinc Genotype 1 HCV Infection	5	01/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.

12/LO/1762	Left ventricular MultiSpot Pacing for CRT (i-Spot)	8	24/12/2015	Open	N/A	No target or date agreed with sponsor.
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infecte	10	19/12/2013	Closed - In Follow Up	N	2 patients recruited.
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	30/06/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progres			Open	N/A	No target or date agreed with sponsor.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologic	3	01/03/2016	Open	Y	Study delivered to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study delivered to time and target.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut	5	01/06/2015	Open	N/A	No target or date agreed with sponsor.
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	2	15/04/2015	Withdrawn	N/A	No target or date agreed with sponsor.
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease (TRx-237-015)	10	01/01/2014	Open	Y	Study delivered to time and target.
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol AI444042	2	30/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	6	01/01/2014	Open	N	7 patients recruited to date.
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	Rare disease study. There were 2 patients recruited.
12/SW/0378	Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	6	31/10/2014	Open	N	Postponed start of recruitment in agreement with sponsor, following bereavement in study team. First patient consented September 2014.
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C	55	30/11/2014	Open	N	There are 41 patients recruited to date.
12/WM/0373	A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics	50	01/11/2015	Open	N/A	No target or date agreed with sponsor.
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	30/06/2014	Open	Y	Study delivered to time and target.
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Lym	2	19/11/2013	Closed - In Follow Up	Y	Study delivered to time and target. Still open.

12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	02/07/2014	Closed - In Follow Up	Y	Study delivered to time and target. 6 patients recruited in total.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	No target or date agreed with sponsor.
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Risistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	1	30/09/2018	Open	Y	Study delivered to time and target. Still open.
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	1	28/02/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/EE/0276	A Phase 3B Randomized, OpenLabel MultiCenter Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	4	01/01/2014	Closed - In Follow Up	Y	Study delivered to time and target. Recruitment far exceeded target of 4 (23 patients recruited to date).
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	12	31/05/2015	Open	N/A	No target or date agreed with sponsor.
13/EE/0365	Investigation of newly developed 1- and 2-piece convex ostomy products in subjects with ileostomy			Withdrawn	N/A	No target or date agreed with sponsor.
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	6		Open	N/A	No date agreed with sponsor. Extended negotiation over contract/budgets.
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	20	31/12/2014	Open	N	There are 5 patients recruited into the study. Team continues to try to identify new patients.
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)			Open	N/A	No target or date agreed with sponsor. There have been 12 patients recruited to date. Although team was consenting and screening early on, there was a high drop-out rate.
13/EN/0348	Safety and Efficacy assessment of MonoprostÂ® (unpreserved latanoprost) in comparison with LumiganÂ® 0.01 % and LumiganÂ® 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by LumiganÂ® 0.01 % with ocular surfac	6	31/08/2015	Open	N/A	No target or date agreed with sponsor.
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	31/05/2014	Closed - Follow Up Complete	N	Several studies were being conducted at the same time at the site. This cause several months of delay in conducting SIV and impacted on site's ability to recruit in that period. Total of 3 patients recruited.
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combinationof ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and BT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults with Genotype 1a Chronic Hepatit	5	01/05/2013	Closed - Follow Up Complete	N	Study had very tight UK set-up timelines; almost fully recruited in the US when UK site was opened. UK site only had 4 days to recruit.

13/LO/0501	A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE	1	31/03/2014	Closed - Follow Up Complete	N	Sponsor required extensive protocol-specific training in various electronic systems; delayed set-up. Recruitment closed by Sponsor before site was able to enrol a patient.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	26/06/2014	Closed - In Follow Up	Y	Study delivered to time and target. 5 patients recruited in total.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301			Closed - In Follow Up	N/A	No target or date agreed with sponsor.
13/LO/0740	A RANDOMIZED, MULTICENTER, DOUBLE BLIND PHASE 3 STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 () BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SY	2	30/06/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4		Open	N	Proposed study regimen would be under-treating patients in relation to another study with the same IMP; therefore difficult to justify enrolling patients into this study. Sponsor is aware of this issue.
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	5		Open	N/A	No date agreed with sponsor.
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	1	31/12/2018	Open	Y	Study delivered to time and target.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tre	4	01/03/2015	Open	Y	Study delivered to time and target.
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Open	Y	Study delivered to time and target.
13/LO/1323	The efficacy and safety of FerriproxÂ® for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	6		Open	N/A	No target or date agreed with sponsor.
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30		Open	N/A	No date agreed with sponsor.
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTIâ^'PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NONâ^'SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	2		Closed - In Follow Up	Y	Study delivered to target. 6 patients recruited in total.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcu	5	31/08/2016	Open	N/A	No target or date agreed with sponsor.

13/LO/1682	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peri	5	31/12/2016	Open	N/A	No target or date agreed with sponsor.
13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimerâ€™s Disease (Prodromal AD).	10		Open	N/A	No target or date agreed with sponsor.
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of PergoverisÂ® (follitropin alfa and lutropin alfa) and GONAL-fÂ® (follitropin alfa) for multifollicular development as part of an a			Open	N/A	No target or date agreed with sponsor.
13/NE/0125	PRESTO Neo.1.C/E	8	01/08/2014	Withdrawn	N	Screened large numbers of patients comparable with other sites but have been unable to recruit. The intervention timing is challenging. Sponsor has acknowledged these challenges across all open sites. Study eventually withdrawn.
13/NE/0126	An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool characteristics in infants with suspected gastrointestinal Non IgE mediated cowâ€™s milk	4	31/10/2014	Open	N	Inclusion criteria still proving to be an obstacle (age of referred children is older and they are therefore excluded). Discussing with Community Allergy nursing re: suitable patients.
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N	Rare disease study.
13/NI/0188	A singlearm trial to evaluate the effectiveness of PCI of de novo 3vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guidance, using an everolimuseluting stent with biodegradable abluminal coating	20	31/12/2019	Open	N/A	No target or date agreed with sponsor.
13/NW/002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEALÂ® Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery (VICTORY Stud	20	31/07/2015	Open	N/A	No target or date agreed with sponsor.
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in ParkinsonÂ's Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	Closed - Follow Up Complete	N	Eligible patients were identified but none agreed/consented to participate or passed screening criteria.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	8	01/01/2014	Open	N	There are 2 patients recruited.
13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	4	31/03/2014	Closed - Follow Up Complete	N	Initially restrictive inclusion/exclusion criteria in original protocol. Substantial Amendments submitted in order to broaden potential patient population. Difficult population group - very sick inpatients, normally on ITU.
13/nw/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Gl			Open	N/A	No target or date agreed with sponsor.
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	5	30/06/2016	Open	N/A	No target or date agreed with sponsor.
13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	1	30/11/2014	Withdrawn	Y	Study delivered to time and target.

13/NW0697	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	8	14/02/2016	Open	N/A	No target or date agreed with sponsor.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A230	6	30/04/2014	Closed - In Follow Up	N	IMP supply delays. 5 patients recruited to date.
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like moleculae 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Closed - Follow Up Complete	N	Study burden on patients excessive / heavy. Difficult for patients to consent and study since closed by Sponsor.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	3	31/10/2014	Open	Y	Study delivered to time and target. Still open.
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabTheraÂ® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 o	3	31/12/2014	Closed - Follow Up Complete	N	Study recruited one subject; not as many eligible patients as expected during the relatively short recruitment window.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	3	01/10/2014	Closed - In Follow Up	Y	Study delivered to time and target. Rare disease study.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Trea	4	21/10/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	20	31/01/2015	Open	N/A	No target or date agreed with sponsor. 4 patients recruited to date.
13/SC/0559	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	2	31/03/2015	Open	N/A	No target or date agreed with sponsor.
13/SC/0589	Optimisation of Onpulse technology for patients with post surgical or vascular oedema	10	30/07/2014	Closed - Follow Up Complete	N	Study completed to target in November 2014.
13/SW/0124	A PERFORMANCE EVALUATION STUDY OF UROSENSâ€™ MCM5-ELISA FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH KNOWN DISEASE AND IN THOSE PRESENTING WITH RAISED SERUM PROSTATE-SPECIFIC ANTIGEN AND/OR ABNORMAL PROSTATE GLAND MORPHOLOGY	19	28/02/2014	Closed - In Follow Up	Y	Study delivered to target.
13/WA/0064	A performance evaluation study of UROSENS Mcm5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	15/01/2014	Open	N	Target of 250 patients reached within 10 months; contract stated 8 months.
13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable P	5	31/12/2014	Withdrawn	N/A	No target or date agreed with sponsor.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	2	31/07/2015	Open	Y	Study delivered to time and target.
13/WS/0172	A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	8	13/12/2015	Open	N/A	No target or date agreed with sponsor.
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions wiht a novel paclitaxel coated percutaneous angioplasty ballon.	10	01/01/2016	Open	N/A	No target or date agreed with sponsor.

13/YH/0174	A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis			Withdrawn	N/A	No target or date agreed with sponsor.
13/YH/0317	Current Steering to Optimize Deep Brain Stimulation	4	31/12/2014	Closed - In Follow Up	Y	Study delivered to time and target.
14/EM/0130	A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment with or without Hematopoietic S	2	28/02/2015	Open	N/A	No target or date agreed with sponsor.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis.	2	14/08/2018	Open	N/A	No target or date agreed with sponsor.
14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	3	28/08/2015	Open	N/A	No target or date agreed with sponsor.
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNaÃ¯ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	4		Closed - In Follow Up	Y	Study delivered to time and target.
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	2	12/05/2020	Open	Y	Study delivered to time and target.
14/LO/0865	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	5		Open	N/A	No target or date agreed with sponsor.
14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTIâˆ’PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NONâˆ’SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAP	4	01/06/2015	Open	N/A	No target or date agreed with sponsor.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	2	01/12/2017	In set up	N/A	No target or date agreed with sponsor.
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	6	31/03/2016	Open	N/A	No target or date agreed with sponsor.
14/NW/0290	Registry of Deep Brain Stimulation with the VERCISEâ„¢ System: Vercise DBS Registry	10		Open	N/A	No target or date agreed with sponsor.
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMERâ€™S DISEASE	6	31/01/2016	Open	N/A	No target or date agreed with sponsor.
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMERâ€™S DISEASE	5	31/01/2016	Open	N/A	No target or date agreed with sponsor.
14/SC/0132	A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.	6		Open	N/A	No target or date agreed with sponsor.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	2	31/08/2016	Open	Y	Study delivered to time and target.
14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)	6	30/09/2015	Open	N/A	No target or date agreed with sponsor.

14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis	2	01/10/2020	Open	N/A	No target or date agreed with sponsor.
14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	6		Open	Y	Study delivered to time and target.
14/YH/0123	An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.	2	30/04/2016	Closed - In Follow Up	Y	Study delivered to time and target.
14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	9		Closed - In Follow Up	Y	Study delivered to time and target.